Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule
Aim: To evaluate the efficacy of locally delivered nanomedicine, vasoactive intestinal peptide in sterically stabilized micelles (VIP-SSM) to the colon and conduct in vitro release studies of a potential oral formulation. Materials & methods: Intracolonic instillation of VIP-SSM was tested in a mouse model of dextran sulfate sodium-induced colitis. Based on the effective mouse dose, human equivalent dose containing nanomedicine powder was filled into enteric coated capsules for in vitro release testing. Results: Colonic delivery of VIP-SSM significantly alleviated colitis. VIP-SSM containing capsules completely dissolved at colonic pH allowing micelles to reform with active VIP. Capsule formulations exhibited reproducible release profiles when stored up to 6 weeks demonstrating stability. Conclusion: VIP-SSM is an effective nanomedicine formulation which appears to have potential for oral treatment of colitis in humans. [Formula: see text].
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 15(2020), 25 vom: 13. Okt., Seite 2459-2474 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dulari Jayawardena [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.07.2021 Date Revised 02.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2020-0280 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315462469 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315462469 | ||
| 003 | DE-627 | ||
| 005 | 20231225154951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2020-0280 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315462469 | ||
| 035 | |a (NLM)32975467 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dulari Jayawardena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.07.2021 | ||
| 500 | |a Date Revised 02.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To evaluate the efficacy of locally delivered nanomedicine, vasoactive intestinal peptide in sterically stabilized micelles (VIP-SSM) to the colon and conduct in vitro release studies of a potential oral formulation. Materials & methods: Intracolonic instillation of VIP-SSM was tested in a mouse model of dextran sulfate sodium-induced colitis. Based on the effective mouse dose, human equivalent dose containing nanomedicine powder was filled into enteric coated capsules for in vitro release testing. Results: Colonic delivery of VIP-SSM significantly alleviated colitis. VIP-SSM containing capsules completely dissolved at colonic pH allowing micelles to reform with active VIP. Capsule formulations exhibited reproducible release profiles when stored up to 6 weeks demonstrating stability. Conclusion: VIP-SSM is an effective nanomedicine formulation which appears to have potential for oral treatment of colitis in humans. [Formula: see text] | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a VIP nanomedicine | |
| 650 | 4 | |a colitis | |
| 650 | 4 | |a colonic delivery | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a oral capsule form | |
| 650 | 4 | |a oral nanomedicine | |
| 650 | 4 | |a slc26a3 | |
| 650 | 4 | |a sterically stabilized micelles | |
| 650 | 4 | |a targeted delivery | |
| 650 | 7 | |a Capsules |2 NLM | |
| 650 | 7 | |a Vasoactive Intestinal Peptide |2 NLM | |
| 650 | 7 | |a 37221-79-7 |2 NLM | |
| 700 | 1 | |a Arivarasu N Anbazhagan |e verfasserin |4 aut | |
| 700 | 1 | |a Priyamvada, Shubha |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Anoop |e verfasserin |4 aut | |
| 700 | 1 | |a Saksena, Seema |e verfasserin |4 aut | |
| 700 | 1 | |a Onyuksel, Hayat |e verfasserin |4 aut | |
| 700 | 1 | |a Pradeep K Dudeja |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 15(2020), 25 vom: 13. Okt., Seite 2459-2474 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2020 |g number:25 |g day:13 |g month:10 |g pages:2459-2474 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2020-0280 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2020 |e 25 |b 13 |c 10 |h 2459-2474 | ||